An Endocrinologist Makes the Case for Peptides
Dr. Edwin Lee is an endocrinologist at UCF, and that matters. Endocrinologists deal with hormones and signaling molecules every day. When someone with that background sits down with Dr. Mark Hyman and says peptides are a big deal, it carries weight that a random influencer recommendation simply cannot match.
This conversation covers a lot of ground, but the thread running through it is straightforward: your body already uses peptides to regulate healing, immune function, and aging. The question is whether supplementing with specific peptides can meaningfully move the needle on those processes.
BPC-157 Gets Its First Human Trial
The biggest news in this episode is the discussion of what appears to be the first formal human trial of BPC-157, focused on knee pain. For years, the knock on BPC-157 has been legitimate: amazing rat data, zero controlled human studies. That gap has been the single biggest obstacle to mainstream acceptance, and it looks like it is finally starting to close.
Lee discusses the trial design and early signals without overstating what preliminary data can tell us. This is exactly the kind of development the peptide space needs. Not more anecdotes, not more forum posts about miraculous recoveries, but actual human data collected under controlled conditions.
Thymosin Alpha-1 and Immune Regulation
Thymosin Alpha-1 does not get the attention of BPC-157 or the growth hormone peptides, but Lee makes a compelling case for why it should. This peptide modulates the immune system, specifically by supporting T-cell function. It has been used clinically in other countries for hepatitis B and as an adjunct in cancer treatment.
For the average person, the relevance is immune resilience. Lee describes using Thymosin Alpha-1 for patients who get sick frequently or whose immune systems seem to underperform. It is not a magic bullet, and it does not replace basic immune health practices like sleep, nutrition, and stress management. But for people who have those foundations in place and still struggle, it is an option worth discussing with a physician.
Epithalon and the Telomere Question
Epithalon is where the conversation gets more speculative. This peptide is linked to telomerase activation, which is the enzyme that maintains telomere length. Shorter telomeres are associated with aging and cellular senescence. The theory is that activating telomerase could slow or partially reverse aspects of biological aging.
The research here is mostly in vitro and animal models. Lee is honest about that. But he explains why longevity researchers find Epithalon interesting and what the potential upside could be if the mechanism translates to humans. It is the kind of long-shot bet that some people in the longevity community are willing to take, even without bulletproof evidence.
GHK Copper Peptides and Collagen
Lee spends time on GHK copper peptides, which are popular in skin care but have broader applications. These peptides stimulate collagen production, promote wound healing, and have anti-inflammatory properties. They are one of the few peptides with both topical and systemic applications.
The collagen discussion connects to a practical concern: as you age, collagen production drops. Your skin thins, your joints stiffen, your gut lining becomes more permeable. GHK copper peptides represent one approach to fighting that decline, though Lee notes that collagen supplementation, adequate protein intake, and vitamin C also matter for collagen synthesis.
NAD+ and Mitochondrial Peptides
The episode wraps with a discussion of NAD+ decline and mitochondrial peptides. NAD+ levels fall with age, and this decline is connected to reduced cellular energy production, impaired DNA repair, and accelerated aging. Lee discusses both NAD+ precursors like NMN and NR, and newer mitochondrial-targeted peptides that aim to support energy production at the cellular level.
This is where peptide therapy intersects with the broader longevity movement. The goal is not to treat a specific injury or condition but to maintain cellular function as you age. It is an ambitious target, and the evidence is still building, but the biological rationale is sound.
The BPC-157 Knee Trial: What Lee Actually Reports
Lee goes into more detail on the human BPC-157 trial than you will find in most podcast discussions. The study focused on patients with knee osteoarthritis, a condition that affects millions and has limited treatment options beyond pain management and eventual joint replacement. Participants received BPC-157 injections directly into the affected knee joint, and the early results showed improvements in both pain scores and functional mobility.
What makes this significant is more than the positive direction of the results, but the fact that the trial exists at all. BPC-157 has been stuck in a credibility limbo for years: hundreds of animal studies showing remarkable healing effects, but no controlled human data to point to. Lee frames this trial as a turning point. Even if the sample size is small and the results are preliminary, it gives physicians something concrete to reference when discussing BPC-157 with patients or with skeptical colleagues. He also notes that the safety profile in the human trial was clean, with no serious adverse events reported, which tracks with the decades of animal safety data.
Epithalon, Telomeres, and the Sleep Connection
The Epithalon discussion takes an interesting turn when Lee connects it to sleep. Most people who hear about Epithalon think of it purely as a longevity peptide because of its effects on telomerase. But Lee describes patients who report noticeably improved sleep quality after starting Epithalon, particularly deeper and more restorative sleep.
The proposed mechanism involves Epithalon's effect on melatonin production. As people age, pineal gland function declines and melatonin output drops. Epithalon appears to support pineal gland function and normalize melatonin secretion, which could explain the sleep improvements patients describe. Lee connects this back to the aging conversation: poor sleep accelerates biological aging through increased inflammation, impaired growth hormone release, and reduced cellular repair. If Epithalon can improve sleep quality by restoring healthier melatonin patterns, the downstream effects on aging could extend well beyond what telomere length alone would predict.
Lee does not claim Epithalon is a proven anti-aging drug. But the combination of telomerase support and improved sleep makes it one of the more interesting peptides in the longevity space, and he uses it with select patients in his practice.
How Lee's Perspective Differs From Other Peptide Advocates
Most peptide content online comes from three types of sources: biohackers sharing personal experiences, compounding pharmacy owners with financial stakes in the market, and general health podcasters summarizing research they read. Lee is none of these. He is a board-certified endocrinologist at a university medical center who prescribes peptides within a clinical framework.
That matters because it changes what "evidence" means in the conversation. When Brigham Buhler (featured in three JRE episodes on FormBlends) talks about BPC-157, he is speaking as someone whose business is affected by peptide regulation. His facts are accurate, but his framing is shaped by his position. When Andrew Huberman covers peptides (also on FormBlends), he is a neuroscientist reviewing the literature from an academic perspective. Lee sits in the middle: he both reviews the research and uses peptides with real patients, monitoring outcomes and adjusting based on what he sees.
The BPC-157 knee trial discussion is a perfect example. Lee does not simply say "this is exciting" and move on. He talks about the study design, what the pain scores and functional outcomes actually mean, and how this data fits into the larger picture of BPC-157 research. He also acknowledges the limitations without using them to dismiss the results. That balance is hard to find in this space, and it is the main reason this episode is worth watching even if you have seen other peptide content.
The Longevity Peptide Stack: What Lee Uses With Patients
Lee gives enough clinical detail in this episode to outline what a longevity-focused peptide protocol looks like in his practice. It is not a single compound. It is a combination designed to address multiple aging pathways simultaneously.
For cellular energy and mitochondrial function, he uses NAD+ precursors (NMN at 500-1,000mg daily) alongside targeted mitochondrial support. For immune resilience, Thymosin Alpha-1 at doses typically ranging from 1.6mg to 3.2mg administered subcutaneously two to three times per week. For tissue repair and anti-inflammatory effects, BPC-157 at 250-500 micrograms daily, often in defined cycles around specific complaints. For collagen support and skin health, GHK copper peptides both topically and sometimes systemically. And for the more speculative longevity angle, Epithalon in short courses aimed at supporting telomerase activity and melatonin production.
Lee is careful to say that this is not a one-size-fits-all approach. Each patient gets a subset of these interventions based on their bloodwork, health goals, and risk tolerance. Some patients want the proven basics (BPC-157 for a specific injury, NAD+ for energy). Others are willing to try the more experimental options like Epithalon with full understanding of the evidence limitations. The individualization is what separates clinical peptide use from the online "stack" culture where people copy protocols from strangers on Reddit.
Questions to Ask Your Endocrinologist About Peptides
If this episode motivates you to bring up peptides with your own doctor, here are questions that will get the most productive conversation started. These are framed for an endocrinologist specifically, since Lee's specialty gives him a different lens than a primary care doctor or a functional medicine practitioner.
1. Based on my hormone levels and metabolic markers, are there any peptides that address gaps in my current health picture?
2. What is your experience with BPC-157 in clinical practice, and what outcomes have you seen?
3. Should I get my IGF-1 tested before considering growth hormone peptides, and what range would make them appropriate or inappropriate for me?
4. Are there any interactions between peptide therapy and the hormone medications I am currently taking?
5. What is your view on Thymosin Alpha-1 for someone who gets sick frequently despite otherwise healthy habits?
6. If I wanted to try a peptide for a specific issue (injury, gut health, sleep), what would a reasonable trial period look like before we evaluate whether it is working?
7. What monitoring schedule would you recommend during peptide treatment?
If your endocrinologist is unfamiliar with peptide therapy, that is not unusual. Peptides are not covered extensively in most residency programs. You might ask for a referral to a physician who specializes in this area, or you can use the clinical framework that Dr. Craig Koniver outlines in his episode on FormBlends as a reference point for what good peptide medical oversight looks like.
Putting the BPC-157 Human Trial in Context
The knee trial Lee discusses is a milestone, but it is worth understanding what it is and what it is not. It is one of the first controlled human studies of BPC-157, which means it starts to close the gap between animal evidence and clinical proof. The fact that the safety data was clean and the outcomes trended positive is encouraging.
But it is a small trial focused on a single application (knee osteoarthritis). It does not validate every claimed use of BPC-157 across gut health, tendon repair, brain injury, and the dozens of other applications seen in animal models. Each of those applications needs its own human trials. The knee data is a proof of concept: BPC-157 can be administered safely in humans and may produce measurable benefits. Extending that to "BPC-157 fixes everything" would be premature.
That said, the clinical community is watching this trial closely. If the results hold up in larger studies, it could open the door to more human research on BPC-157 for other indications. Lee frames this as the beginning of a validation process, not the end of one. For patients using BPC-157 now based on the strong animal data and clinical anecdote, this trial provides some additional confidence. For skeptics who have been waiting for human evidence, it provides a starting point. Both positions are reasonable, and Lee holds them in balance better than most commentators in this space.
Why This Conversation Matters
Dr. Lee brings something rare to the peptide conversation: he is a specialist in the exact systems that peptides target. He understands hormone signaling, immune regulation, and aging biology at a level that most peptide advocates do not. That expertise lets him separate plausible mechanisms from wishful thinking, and his willingness to flag uncertainty makes his optimism more credible, not less.